Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | EDNRA | P25101 | 1/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 4/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.62 |
| ▸ | SCN1A | P35498 | 2/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.62 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.62 |
| ▸ | SCN4A | P35499 | 1/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27575105 | 0.98 | ALDH1A1 (0.69) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL3070565 | 0.94 | ALDH1A1 (0.68) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| Trifluoroacetic Acid SCHEMBL19616930 | 0.89 | SCN3A (0.59) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL1576701 | 0.89 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL3050459 | 0.85 | SCN3A (0.65) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL3066836 | 0.85 | LMNA (0.79) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL3476554 | 0.84 | ALDH1A1 (0.60) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL3002532 | 0.83 | ALDH1A1 (0.68) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL184078 | 0.83 | ALDH1A1 (0.72) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 | |
| SCHEMBL183995 | 0.83 | ALDH1A1 (0.72) | ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117043156-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-11-10 | — | — | CN | claimed |
| EP-3389654-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | claimed |
| CN-113166122-A | Small molecule inhibitors of galectin-3 | 百时美施贵宝公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2020248123-A1 | HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | WO | claimed |
| WO-2019217822-A1 | COMPOUNDS AND METHODS OF USING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY CONDITIONS | CHROMOCELL CORPORATION (US) | 2019-11-14 | — | — | WO | claimed |
| WO-2019200369-A1 | COMPOUNDS AND METHODS OF USING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF PERIPHERAL NERVE DAMAGE | CHROMOCELL CORPORATION (US) | 2019-10-17 | — | — | WO | claimed |
| EP-3458449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-03-27 | — | — | EP | claimed |
| CN-109526219-A | Benzsulfamide and its purposes as therapeutic agent | 泽农医药公司 | 2019-03-26 | — | — | CN | claimed |
| CN-108699015-A | Diamines-the aryl sulphur amine compound substituted to hydroxy alkyl amine-of the voltage gated sodium channels with selective active and hydroxycycloalkyl amine- | 默沙东公司 | 2018-10-23 | — | — | CN | claimed |
| CN-108349963-A | sodium channel blockers | 株式会社大熊制药 | 2018-07-31 | — | — | CN | claimed |
| WO-2016040315-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2016-03-17 | — | — | WO | claimed |
| WO-2015080988-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-06-04 | — | — | WO | claimed |
| CN-101899010-A | Quinazol derivative, preparation method and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2010-12-01 | — | — | CN | claimed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | claimed |
| EP-1551396-A1 | PIN1-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Pintex Pharmaceuticals, Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | claimed |
| WO-2004093803-A2 | PHOTOCHEMOTHERAPEUTIC COMPOUNDS FOR USE IN TREATMENT OF PIN1-ASSOCIATED STATES | PINTEX PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040214872-A1 | Pin1-modulating compounds and methods of use thereof | PINTEX PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| EP-1389202-B1 | 2,6-SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORP (US) | 2004-09-29 | — | — | EP | claimed |
| WO-2004028535-A1 | PIN1-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PINTEX PHARMACEUTICALS, INC. (US) | 2004-04-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214872-A1 | Pin1-modulating compounds and methods of use thereof | PIN1, FKBP14, PIN4 | ALDH1A1 4434/4885LMNA 3904/4885SMN1; SMN2 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.